Entrar/Registro  
INICIO ENGLISH
 
Gaceta Médica de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Gaceta Médica de México >Año 2015, No. 3


Zamora-Pérez E, López-Karpovitch X
Factores predictivos de respuesta hematológica en adultos con síndrome mielodisplásico (SMD) tratados con ciclosporina A (CSA)
Gac Med Mex 2015; 151 (3)

Idioma: Español
Referencias bibliográficas: 42
Paginas: 345--353
Archivo PDF: 255.63 Kb.


Texto completo




RESUMEN

Antecedentes: Los SMD son enfermedades clonales de las células hematopoyéticas. La escala de riesgo más utilizada es el International Prognostic Scoring System (IPSS). La CSA se ha empleado para tratar las citopenias en los SMD. Objetivo: Evaluar la respuesta hematológica e identificar factores predictivos de respuesta en adultos con SMD tratados con CSA. Material y métodos: Se incluyeron pacientes con SMD diagnosticados de acuerdo con los criterios de la Organización Mundial de la Salud (OMS). Se usaron las escalas de riesgo IPSS, IPSS revisado (IPSS-R), WHO Prognostic Scoring System (WPSS) y WPSS revisado (WPSS-R). La dosis inicial de CSA fue de 5 mg/kg/día. Resultados: Cumplieron con los criterios de inclusión 32 pacientes. La mediana de edad fue de 56.5 años y la de seguimiento, de 3.1 años. Se obtuvo una tasa de respuesta hematológica del 56.2% y una independencia de trasfusión de concentrados eritrocitarios (CE) del 42.9%. La edad, la cifra de hemoglobina (Hb) y la escala WPSS en el momento del diagnóstico fueron factores independientes predictivos de respuesta para CSA. La supervivencia entre los pacientes con respuesta a CSA fue mayor que la de aquellos sin respuesta (p = 0.06). Conclusiones: La CSA indujo respuesta hematológica › 50% de pacientes con SMD, ‹ 57 años de edad, Hb ‹ 8 g/dl y WPSS bajo en el momento del diagnóstico.


Palabras clave: Síndromes mielodisplásicos, Ciclosporina A, Clasificaciones de riesgo, Respuesta hematológica, Supervivencia.


REFERENCIAS

  1. Nimmer SD. Myelodysplastic syndromes. Blood. 2008;111(10):4841-51.

  2. Gattermann CA, Schneider W. Age related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992;82(2):358-67.

  3. Greenberg PL, Cox C, LeBau MM, et al. International scoring system for evaluation prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-88.

  4. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes. Blood. 2012;120(12):2454-65.

  5. Malcovati L, Germing U, Kuendden A, et al. Time-dependent Prognosis Scoring System for predicting survival and Leukemic evolution in Myelodysplastic Syndromes. J Clin Oncol. 2007;25(23):3503-10.

  6. Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96(10):1433-40.

  7. Tefferi A, Vardiman JW. Myelodysplastic Syndromes. N Engl J Med. 2009;361(19):1872-85.

  8. López-Karpovitch X, Barrales-Benítez O, Flores M, Piedras J. Effect of azacytidine in the release of leukemia inhibitory factor, oncostatin M, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia. Cytokine, 2002;20(4):154-62.

  9. Voulgarelis M, Giannouli S, Ritis K, et al. Myelodysplasia associated autoimmunity: Clinical and pathophysiologic concepts. Eur J Clin Invest. 2004;34(10):690-700.

  10. Barrett AJ, Sloand E. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica. 2009;94(4):449-51.

  11. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte- mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol. 1998;102(5):1314-22.

  12. Parikh AR, Olnes MJ, Barrett AJ. Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab. Sem Hematol. 2012;49(4):304-11.

  13. Nguyen PL. The Myelodysplastic Syndromes. Hematol Oncol Clin N Am. 2009;23(4):675-91.

  14. Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol. 2008;83(10): 765-70.

  15. National Comprehesive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology-Myelodysplastic Syndromes. Version 2.2013;pp12/53.

  16. Sellery C, Maciejewski JP, Catalano L, et al. Effects of cyclosporin on hematopoietic and immune functions in patients with hypoplastic myelodisplasia. In vitro and in vivo studies. Cancer. 2002;95(9):1911-22.

  17. Miesher PA. Autoimmune myelodysplasias. Sem Hematol. 1991;28(4): 322-30.

  18. Mueller EW, deWolf JTM, Vellenga E. Successful immunosupresive treatment after failure of eritropoietic therapy in two subjects with refractory anaemia. Br J Haematol. 1993;83(1):171-2.

  19. Xiao Z, Xu Z, Zhang Y, Qin T, Zhang H, Fang L. Cyclosporin A and thalidomide in patients with myelodysplastic syndromes: Results of a pilot study. Leuk Res. 2011;35(1):61-5.

  20. Shimamoto T, Tohyama K, Okamoto T, et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan, Leuk Res. 2003;27(9):783-8.

  21. Jonásova A, Neuwirtová R, Cermák J, et al. Cyclosporin A therapy in hypoplastic Myelodisplastic Syndromes patients and certain refractory anaemia without hypoplastic bone marrow. Br J Haematol. 1998;100(2):304-9.

  22. Shimamoto T, Ohyashiki K. Immunosuppressive Treatments for Myelodysplastic Syndromes. Leuk Lymph. 2003;44(4):593-604.

  23. Dixit A, Chatterjee T, Mishra P, et al. Cyclosporin A in myelodysplastic syndrome: a preliminary report. Ann Hemathology. 2005;84(9):565-8.

  24. Chen S, Jiang B, Da W, Gong M, Guan M. Treatment of myelodysplastic syndrome with cyclosporine A. Int J Hematol. 2007;85(1):11-7.

  25. Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with MDS treated with immunosuppressive therapy. J Clin Oncol. 2008;26(15):2505-11.

  26. Ishikawa T, Tohyama K, Nakao S, et al. A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-) CD59 (-) blood cells predicts platelet response. Int J Hematol. 2007;86(2):150-7.

  27. Catalano L, Selleri C, Califano C, et al. Prolonged response to cyclosporin- A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica. 2000;85(2):133-8.

  28. Mahesh S, Ginzburg Y, Verma A. Iron overload in myelodysplastic syndromes. Leuk Lymp. 2008;49(3):427-38.

  29. Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res. 2007;31 Suppl 3:S2-6.

  30. Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes. En: Swerdlow SH, Campo E, Harris NL, et al., editores. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008. p. 88-107.

  31. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-25.

  32. Bowen D, Culligan D, Jowirr S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003;120(2):187-200.

  33. Mc Laren CE, Barton JC, Adams PC, et al. Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci. 2003;325(2):53-62.

  34. Stone RM. How I treat patients with myelodysplastic syndrome. Blood. 2009;113(25):6296-303.

  35. Broliden A, Dahl IM, Hast R, et al. Antithymocite globulin and cyclosporine A as combination therapy for low risk non-sideriblastic myelodysplastic syndromes. Haematologica. 2006;91(5):667-70.

  36. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ. A simple method to predict response to immunosupresive therapy in patients with myelodysplastic syndrome. Blood. 2003;102(8):3025-7.

  37. Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocite globulin for treatment of the bone marrow failure associated with myelodysplastic syndrome. Ann Intern Med. 2002;137(3):156-63.

  38. Passweg JR, Giagounidis AA, Simcock M, et al. Immnusupresive therapy for patients with myelodysplastic syndrome: A prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/99. J Clin Oncol. 2011;29(3):303-9.

  39. Yue G, Hao S, Fadare O, et al. Hypocellularity in myelodysplastic síndrome is an independent factor whichs predicts a favorable outcome. Leuk Res. 2008;32(4):553-8.

  40. Ogata M, Ohtsuka E, Imamura T, et al. Response to cyclosporine therapy in patients with myelodysplastic syndrome: a clinical study of 12 cases and literature review. Int J Hematol. 2004;80(1):35-42.

  41. Barrett J, Sloand E, Young N. Determining which patients with myelodysplastic syndrome will response to immunosuppressive treatment. Hematologica. 2006;91(5):583-4.

  42. Sauntharajah Y, Nakamura R, Nam JM, et al. HLA-DR15(DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosupresion in myelodysplastic syndrome. Blood. 2002;100(5):1570-4.



>Revistas >Gaceta Médica de México >Año2015, No. 3
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019